Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
{{output}}
Background: Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). ... ...
